Monarch Medical Technologies, the pioneer and leader in clinical decision support for drug dosing in hospitalized patients, today announced that Glenn Petracci has joined the company as its new senior vice president of sales and marketing. Formerly the vice president of sales for Capsule Tech, Inc., Petracci brings more than 25 years of experience in both the clinical and business aspects of healthcare and information technology.

“Glenn’s deep understanding of the complexities of the health information technology market, as well as his extensive experience in hospitals with complex healthcare IT solution makes him a valuable asset to the Monarch team,” said Stuart Long, chief executive officer of Monarch Medical Technologies. “With a track record of driving strong sales growth in highly competitive markets while forging strong relationships with customers, Glenn will be a key part of a strong team to help establish Monarch as the go-to company for mitigating the risks that can be associated with drugs and point-of-care dosing processes.”

Prior to joining Capsule Tech, Petracci held executive sales and marketing positions at Philips Healthcare, RecoverCare, L.L.C., Sten-Barr Medical, and AMICAS. In addition, he worked with FUJIFILM Medical Systems U.S.A., Inc., UroCor, Inc., Nycomed/Amersham and St. Christopher’s Hospital for Children in Philadelphia.

“The advancements Monarch brings to the market with the EndoTool platform are essential for every hospital in the United States,” Petracci said. “I am looking forward to the chance to help hospitals meet their own patient safety goals, as well as the standards they are being held accountable to in today’s healthcare environment.”

Monarch is the developer of the EndoTool® glucose management clinical decision support platform, a market-leading suite of advanced dosing algorithm software applications recognized for the ability to provide unsurpassed patient-specific glycemic control across a broad population of patients. Most recently, the company received clearance in April from the U.S. Food and Drug Administration for EndoTool IV™, the latest application in the suite of products for both adult and pediatric patients.

About Monarch Medical Technologies

Monarch Medical Technologies is a privately held medical technology company founded by clinicians with a vision of dramatically improving hospital-based glucose management by replacing traditional “paper and pencil” linear protocols with individualized and predictive computer-based solutions. With the launch of its flagship product, the EndoTool Glucose Management System, the company pioneered the field of predictive therapeutic control technologies for managing drugs of concern. Formerly the EndoTool division of Hospira Worldwide, a leading Fortune 1000 healthcare company, the company was strategically acquired in October 2012 by private equity firm Eigen Capital Partners.